{"name":"Steba Biotech S.A.","slug":"steba-biotech-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"TOOKAD VTP","genericName":"TOOKAD VTP","slug":"tookad-vtp","indication":"Localized prostate cancer (intermediate and high-risk disease)","status":"marketed"},{"name":"TOOKAD® Soluble","genericName":"TOOKAD® Soluble","slug":"tookad-soluble","indication":"Localized prostate cancer (intermediate and high-risk disease)","status":"phase_3"},{"name":"padeliporfin VTP","genericName":"padeliporfin VTP","slug":"padeliporfin-vtp","indication":"Treatment of metastatic liver cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"WST 11 -mediated -VTP","genericName":"WST 11 -mediated -VTP","slug":"wst-11-mediated-vtp","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"WST 11 -mediated -VTP","genericName":"WST 11 -mediated -VTP","slug":"wst-11-mediated-vtp","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TOOKAD VTP","genericName":"TOOKAD VTP","slug":"tookad-vtp","phase":"marketed","mechanism":"TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis.","indications":["Localized prostate cancer (intermediate and high-risk disease)"],"catalyst":""},{"name":"TOOKAD® Soluble","genericName":"TOOKAD® Soluble","slug":"tookad-soluble","phase":"phase_3","mechanism":"TOOKAD Soluble is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature.","indications":["Localized prostate cancer (intermediate and high-risk disease)"],"catalyst":""},{"name":"padeliporfin VTP","genericName":"padeliporfin VTP","slug":"padeliporfin-vtp","phase":"phase_3","mechanism":"Padeliporfin VTP is a photosensitizer that selectively targets and destroys cancer cells upon activation by light.","indications":["Treatment of metastatic liver cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":1,"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}